Literature DB >> 10916147

Intranasal vaccines: forthcoming challenges.

.   

Abstract

The mucosal epithelium of the upper respiratory tract constitutes an effective physical barrier to many pathogens. Its mucosal-associated lymphoid tissue is of particular importance for the protection and integrity of mucosal surfaces and the body's interior. Understanding the factors that influence the induction and regulation of mucosal immune responses will facilitate the design of vaccines capable of eliciting the appropriate type of protective immune response.

Year:  2000        PMID: 10916147     DOI: 10.1016/s1461-5347(00)00281-9

Source DB:  PubMed          Journal:  Pharm Sci Technolo Today        ISSN: 1461-5347


  13 in total

1.  Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague.

Authors:  Devender Kumar; Girish Kirimanjeswara; Dennis W Metzger
Journal:  Clin Vaccine Immunol       Date:  2011-08-31

2.  NK cells influence both innate and adaptive immune responses after mucosal immunization with antigen and mucosal adjuvant.

Authors:  Lindsay J Hall; Simon Clare; Gordon Dougan
Journal:  J Immunol       Date:  2010-03-10       Impact factor: 5.422

3.  Outer membrane vesicles derived from Salmonella Typhimurium mutants with truncated LPS induce cross-protective immune responses against infection of Salmonella enterica serovars in the mouse model.

Authors:  Qiong Liu; Qing Liu; Jie Yi; Kang Liang; Tian Liu; Kenneth L Roland; Yanlong Jiang; Qingke Kong
Journal:  Int J Med Microbiol       Date:  2016-08-25       Impact factor: 3.473

4.  Intranasal immunization with a colloid-formulated bacterial extract induces an acute inflammatory response in the lungs and elicits specific immune responses.

Authors:  A Rial; D Lens; L Betancor; H Benkiel; J S Silva; J A Chabalgoity
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

5.  Modulation of protective immunity against herpes simplex virus via mucosal genetic co-transfer of DNA vaccine with beta2-adrenergic agonist.

Authors:  Seong Bum Kim; Young Woo Han; M M Rahman; Seon Ju Kim; Dong Jin Yoo; Seong Ho Kang; Koanhoi Kim; Seong Kug Eo
Journal:  Exp Mol Med       Date:  2009-11-30       Impact factor: 8.718

6.  Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge.

Authors:  A S Beignon; J P Briand; S Muller; C D Partidos
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

7.  The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skin.

Authors:  A-S Beignon; J-P Briand; R Rappuoli; S Muller; C D Partidos
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

Review 8.  Advances in gene-based vaccine platforms to address the COVID-19 pandemic.

Authors:  Deborah Pushparajah; Salma Jimenez; Shirley Wong; Hibah Alattas; Nafiseh Nafissi; Roderick A Slavcev
Journal:  Adv Drug Deliv Rev       Date:  2021-01-07       Impact factor: 17.873

9.  Preparation and efficacy of a live newcastle disease virus vaccine encapsulated in chitosan nanoparticles.

Authors:  Kai Zhao; Gang Chen; Xing-Ming Shi; Ting-Ting Gao; Wei Li; Yan Zhao; Feng-Qiang Zhang; Jin Wu; Xianlan Cui; Yun-Feng Wang
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

10.  Outer membrane vesicles from flagellin-deficient Salmonella enterica serovar Typhimurium induce cross-reactive immunity and provide cross-protection against heterologous Salmonella challenge.

Authors:  Qiong Liu; Qing Liu; Jie Yi; Kang Liang; Bo Hu; Xiangmin Zhang; Roy Curtiss; Qingke Kong
Journal:  Sci Rep       Date:  2016-10-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.